Search
for
Sort by
Research 361–390 of 777
- Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
- Prediction of the Mechanism of Shaoyao Gancao Decoction in the Treatment of Alopecia Areata by Network Pharmacology and Its Preliminary Verification Study
- AIRE Deficiency Leads to the Development of Alopecia Areata‒Like Lesions in Mice
- The Diverse Experiences and Challenges of Individuals With Alopecia Areata: Survey Results From Finland
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- Alopecia Areata in Latin America: Where are We and Where are We Going?
- The X Factor in Immunity: Sex Differences Shaped by the X Chromosome
- Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
- Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
- Frontal Fibrosing Alopecia. An Example of Disrupted Aryl Hydrocarbon Receptor-Mediated Immunological Homeostasis in the Skin?
- European expert consensus statement on the systemic treatment of alopecia areata
- Update From Dermatology Nurses’ Association Convention 2025
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- The Sebaceous Gland - Friend or Foe?
- An updated review of the sebaceous gland and its role in health and diseases Part 2: Pathophysiological clinical disorders of sebaceous glands
- 056 IKZF1 and IKAROS overexpression contributes to the pathogenesis of alopecia areata
- <i>IKZF1</i> and Ikaros Overexpression Results in Alopecia Areata‐Like Phenotype in Mice
- <div>Six years of the IP Indian Journal of Clinical and Experimental Dermatology (2019-2025):&nbsp;<span style="font-size: 1rem;">A bibliometric and thematic analysis</span></div>
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Keratin 6A promotes skin inflammation through JAK1-STAT3 activation in keratinocytes
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- JAK1 Signaling Is Involved in the Induction of Mechanical Alloknesis in Atopic Dermatitis
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata